Selank

Selank is a synthetic peptide people discuss for quieter anxiety, less rumination and easier social or work situations. Favorable accounts describe calm while staying engaged; other people feel nothing, become sleepy or develop worse anxiety. Nasal and injected experiences differ, and neither a reported amount nor a calming reputation predicts the response.

A short peptide developed from tuftsin. Selank is a seven-amino-acid chain, TKPRPGP, derived from a naturally occurring peptide. The Russian product is nasal drops; community discussion also involves research sprays and subcutaneous injection, meaning injection beneath the skin. Those products and routes are not interchangeable. Selank nasal drops: manufacturer instruction (Official context · Accessed 2026-09-30) · Selank effects: route differences and nonresponse (Community discussion · Accessed 2026-09-30)

Plain Selank differs from modified Selank and Semax. N-Acetyl Selank and N-Acetyl Selank Amidate are modified forms, with separate reports and amounts. Semax is another peptide, usually cast as the activating half of a calm-focus pairing. Claims of longer-lasting modified forms do not establish a conversion between their doses. Selank/Semax IN experiences (Community discussion · Accessed 2026-09-30)

Source context — Selank nasal drops: manufacturer instruction: Manufacturer labeling, not independent replication; passage does not supply PK population, assay or an elimination half-life. Applies to that nasal product, not gray-market sprays, injections or modified analogs. No preparation directions reproduced.

Source context — Selank effects: route differences and nonresponse: Plain and modified Selank discussion is interleaved. Amount unstated in the route-duration comparison. Preferences are not controlled comparisons. No identity, purity or clinical assessment. Preparation and purchase advice excluded.

Source context — Selank/Semax IN experiences: Mixed compounds and variants; paired report cannot establish Selank-only cognitive benefit. Replies recommend regimens and include preparation material, which are not adopted. Route superiority and analog potency claims are opinions.

Less background tension, rather than a high. A solo nasal-course author described less reactivity and smoother thinking, with clearer improvement on days 4–5 and 6–9. They did not report a big mood lift and thought clearer thinking might follow reduced anxiety rather than a separate cognitive effect. Day 10 of 14 day Selank cycle: 750 mcg intranasal (Community discussion · Accessed 2026-09-30)

Situational calm can be the useful change. An airport-travel account named 300 mcg intranasally and less anxiety across two uses. This is a narrow personal experience. Other contributors describe relaxation or sleepiness, while a mixed Selank/Semax user reported no effects by day five. Selank effects: route differences and nonresponse (Community discussion · Accessed 2026-09-30) · No effects on Semax/Selank (Community discussion · Accessed 2026-09-30)

A calming reputation does not prevent activation or low mood. The 250 mcg account described depression-like episodes, rumination, chest tightness and vivid dreams. The recent 100 mcg/spray account described racing thoughts, faster heart rate and poor sleep on later nights. A reply's accumulation explanation is speculation, not a diagnosis. Negative experience on Selank: any alternatives? (Community discussion · Accessed 2026-09-30) · My recent experience with Selank (Community discussion · Accessed 2026-09-30)

Source context — Day 10 of 14 day Selank cycle: 750 mcg intranasal: Anonymous uncontrolled accounts; no product assay. Nasal post covers day ten of planned 14 days, not a completed trial. Same-author later persistence is unverified. Separate injected account lacks frequency and includes sertraline. Claims about adaptation, route superiority and hundreds of users are not accepted.

Source context — Selank effects: route differences and nonresponse: Plain and modified Selank discussion is interleaved. Amount unstated in the route-duration comparison. Preferences are not controlled comparisons. No identity, purity or clinical assessment. Preparation and purchase advice excluded.

Source context — No effects on Semax/Selank: Two compounds together, plain-versus-modified identity not analytically verified. Later nasal amount unstated. Liver explanation is speculation. Replies about Semax alone are not Selank evidence.

Source context — Negative experience on Selank: any alternatives?: Route unstated; daily opening clarified as five days/week. Other stack use not fully described. No causal diagnosis, verified severity or clinical follow-up. Deleted replies are not reconstructed.

Source context — My recent experience with Selank: Nasal spray content unverified; timing and heart rate self-reported. Other historical medication responses do not establish current co-use. The few-hours half-life and accumulation explanation have no supporting measurement. No prevalence inference.

Nasal examples: 750 mcg/day, split two different ways. One solo author reported 375 mcg morning plus 375 mcg midday. A separate r/Peptides reply described 250 mcg three times daily. Equal daily totals do not establish equal effects or delivered amounts. Day 10 of 14 day Selank cycle: 750 mcg intranasal (Community discussion · Accessed 2026-09-30) · Selank/Semax IN experiences (Community discussion · Accessed 2026-09-30)

Nasal chart talk: 250–900 mcg/day; 250–500 mcg per use. The preserved discussion describes the daily band across 1–3 administrations and the per-use band once or twice daily. It also retains lower 200–300 mcg/day charts, 300 mcg 2–3 times daily, and higher 600–1,200+ mcg/day charts. These overlap without defining a dose ladder.

Subcutaneous reports: 500 mcg/day and 500 mcg with frequency unstated. One evening user reported 500 mcg daily for three weeks. A different day-ten commenter named 500 mcg while taking sertraline, without stating injection frequency. Another Selank/Semax account used 500 mcg of each daily and felt nothing. Selank effects: route differences and nonresponse (Community discussion · Accessed 2026-09-30) · Day 10 of 14 day Selank cycle: 750 mcg intranasal (Community discussion · Accessed 2026-09-30) · No effects on Semax/Selank (Community discussion · Accessed 2026-09-30)

Other injection-chart amounts remain separate. Preserved talk includes 150–250 mcg/day, 150–300 mcg once daily, 200–500 mcg/day once daily, and a 400 mcg morning log. A commercial 0.5 mg injection chart is vendor advice, not a human protocol. Assumed greater bioavailability does not supply a nasal-to-injection conversion.

Spray counts are not universal micrograms. The original record lists commercial sprays claiming 100–300 mcg per actuation and secondary drop arithmetic claiming 75 mcg/drop. Device output, formulation and identity matter. A recent adverse report involved a spray labeled 100 mcg; a small labeled amount did not guarantee a mild experience. My recent experience with Selank (Community discussion · Accessed 2026-09-30)

Source context — Day 10 of 14 day Selank cycle: 750 mcg intranasal: Anonymous uncontrolled accounts; no product assay. Nasal post covers day ten of planned 14 days, not a completed trial. Same-author later persistence is unverified. Separate injected account lacks frequency and includes sertraline. Claims about adaptation, route superiority and hundreds of users are not accepted.

Source context — Selank/Semax IN experiences: Mixed compounds and variants; paired report cannot establish Selank-only cognitive benefit. Replies recommend regimens and include preparation material, which are not adopted. Route superiority and analog potency claims are opinions.

Source context — Selank effects: route differences and nonresponse: Plain and modified Selank discussion is interleaved. Amount unstated in the route-duration comparison. Preferences are not controlled comparisons. No identity, purity or clinical assessment. Preparation and purchase advice excluded.

Source context — No effects on Semax/Selank: Two compounds together, plain-versus-modified identity not analytically verified. Later nasal amount unstated. Liver explanation is speculation. Replies about Semax alone are not Selank evidence.

Source context — My recent experience with Selank: Nasal spray content unverified; timing and heart rate self-reported. Other historical medication responses do not establish current co-use. The few-hours half-life and accumulation explanation have no supporting measurement. No prevalence inference.

Nasal: within minutes in some accounts; 15–60 minutes in chart talk. ELROCK reported calm within minutes. A separate gifted-product log described alertness around ten minutes after two sprays. The preserved 15–60-minute estimate is community timing, not a blood measurement. Sensation, useful anxiety relief and no response are different outcomes. Selank experience? (Community discussion · Accessed 2026-09-30) · Nasal Selank Log (Community discussion · Accessed 2026-09-30)

One injected account: 25–35 minutes. Old-Yogurtcloset-738 contrasted this with nearly immediate nasal effects; the amount was unstated. Other posters dispute route preference. A multi-day improvement during a course is separate from onset after one administration. Selank effects: route differences and nonresponse (Community discussion · Accessed 2026-09-30) · Day 10 of 14 day Selank cycle: 750 mcg intranasal (Community discussion · Accessed 2026-09-30)

Nasal accounts differ: about half an hour versus up to three hours. Old-Yogurtcloset-738 described roughly half an hour nasally and over four hours after injection. ELROCK's separate nasal account lasted at most about three hours. The preserved 3–6-hour chart estimate is another claim; these are not controlled route comparisons. Selank effects: route differences and nonresponse (Community discussion · Accessed 2026-09-30) · Selank experience? (Community discussion · Accessed 2026-09-30)

About 2 minutes, about 10 minutes, and a few hours are conflicting claims. The preserved secondary-summary lore quotes about 2 minutes. An AnabolicMinds poster recalled about 10 minutes for injectable Selank; a recent Reddit reply asserted a few hours without measurements. Their underlying origins are unverified. These are not a measured human range, and felt calm cannot settle the disagreement. Nasal Selank Log (Community discussion · Accessed 2026-09-30) · My recent experience with Selank (Community discussion · Accessed 2026-09-30)

Label kinetics do not supply the community half-life. The manufacturer reports nasal bioavailability of 92.8%, blood detection at 30 seconds and decline over 5–5.5 minutes, without calling that elimination half-life. The labeled-peptide abstract supplies no numeric human half-life. The leaflet's 14-day course and 1–3-week repeat interval are product context. Selank nasal drops: manufacturer instruction (Official context · Accessed 2026-09-30) · Zolotarev et al. 2006: tritium-labeled peptides and biodegradation (Official context · Accessed 2026-09-30)

Source context — Selank experience?: No analytical product verification; amount per spray not established for ELROCK. Adjacent hearsay is not his duration measurement. Potential commercial forum context and sourcing exchanges are not adopted.

Source context — Nasal Selank Log: Gifted-product and supplement-representative context; author uses third-person subject language. Exact administered micrograms unconfirmed. Recalled injectable half-life has no primary citation. Subjective stimulation is not measured blood PK or a representative calm response.

Source context — Selank effects: route differences and nonresponse: Plain and modified Selank discussion is interleaved. Amount unstated in the route-duration comparison. Preferences are not controlled comparisons. No identity, purity or clinical assessment. Preparation and purchase advice excluded.

Source context — Day 10 of 14 day Selank cycle: 750 mcg intranasal: Anonymous uncontrolled accounts; no product assay. Nasal post covers day ten of planned 14 days, not a completed trial. Same-author later persistence is unverified. Separate injected account lacks frequency and includes sertraline. Claims about adaptation, route superiority and hundreds of users are not accepted.

Source context — My recent experience with Selank: Nasal spray content unverified; timing and heart rate self-reported. Other historical medication responses do not establish current co-use. The few-hours half-life and accumulation explanation have no supporting measurement. No prevalence inference.

Source context — Selank nasal drops: manufacturer instruction: Manufacturer labeling, not independent replication; passage does not supply PK population, assay or an elimination half-life. Applies to that nasal product, not gray-market sprays, injections or modified analogs. No preparation directions reproduced.

Source context — Zolotarev et al. 2006: tritium-labeled peptides and biodegradation: Only abstract inspected via Europe PMC core API; HTML pages did not render. Species not specified in this abstract, so not relabeled as a human PK study. No full-text numeric clearance claim.

A planned 14-day nasal course; a three-week injected account. The nasal author posted at day ten, then later described lower anxiety about a month after stopping. The 500 mcg/day injected author was three weeks into an intended four-week course. These do not establish lasting drug exposure or an effective break length. Day 10 of 14 day Selank cycle: 750 mcg intranasal (Community discussion · Accessed 2026-09-30) · Selank effects: route differences and nonresponse (Community discussion · Accessed 2026-09-30)

Chart patterns: 14–21 days, two to four weeks, or about 30 days. Preserved discussion also includes days-to-weeks off, two to four weeks on/off, and situational use before stressful events. Short courses being called incomplete is theory, not proof. No shared tolerance-free calendar emerges.

Benefit can build, fade or reverse. A Selank/Semax user reported change around one to two months, with caffeine also present. A recent nasal commenter reported benefit fading within a week despite later breaks. The 250 mcg adverse author clarified five days/week after two initially calmer weeks; their route was unstated. Selank/Semax IN experiences (Community discussion · Accessed 2026-09-30) · My recent experience with Selank (Community discussion · Accessed 2026-09-30) · Negative experience on Selank: any alternatives? (Community discussion · Accessed 2026-09-30)

Source context — Day 10 of 14 day Selank cycle: 750 mcg intranasal: Anonymous uncontrolled accounts; no product assay. Nasal post covers day ten of planned 14 days, not a completed trial. Same-author later persistence is unverified. Separate injected account lacks frequency and includes sertraline. Claims about adaptation, route superiority and hundreds of users are not accepted.

Source context — Selank effects: route differences and nonresponse: Plain and modified Selank discussion is interleaved. Amount unstated in the route-duration comparison. Preferences are not controlled comparisons. No identity, purity or clinical assessment. Preparation and purchase advice excluded.

Source context — Selank/Semax IN experiences: Mixed compounds and variants; paired report cannot establish Selank-only cognitive benefit. Replies recommend regimens and include preparation material, which are not adopted. Route superiority and analog potency claims are opinions.

Source context — My recent experience with Selank: Nasal spray content unverified; timing and heart rate self-reported. Other historical medication responses do not establish current co-use. The few-hours half-life and accumulation explanation have no supporting measurement. No prevalence inference.

Source context — Negative experience on Selank: any alternatives?: Route unstated; daily opening clarified as five days/week. Other stack use not fully described. No causal diagnosis, verified severity or clinical follow-up. Deleted replies are not reconstructed.

Calm-focus stacks complicate attribution. Semax and Selank are often discussed within the same course, at different times of day or together, without a fixed ingredient ratio. Preserved pairings also include Noopept, caffeine/L-theanine, racetams and cognitive or sleep peptides. Changes in sleep, therapy and caffeine intake further complicate attribution; these accounts cannot isolate Selank's contribution. Selank/Semax IN experiences (Community discussion · Accessed 2026-09-30)

Semax + Selank (dominant pair): “Focus stack” / “calm focus” — Semax for activating attention, Selank for anxiolysis. Often same course length and both nasal. Ratio talk is usually independent full doses of each, not a fixed mg:mg blend. [community]

NA-Semax Amidate + Selank or NA-Selank Amidate: Same typology with modified analogs when users want longer perceived duration or different spray stock. [community]

Timing within the pair: Some run Semax-class earlier in the day and Selank later (or both multi-dose); others dose together. Not standardized. [community]

Noopept + Selank: Occasional memory/focus + anxiety-control pairing in older nootropic stacks. [community]

Caffeine / L-theanine layer: Common lifestyle stack; watch overstimulation if Semax is also present. [community]

Racetams / other nootropics: Piracetam, phenylpiracetam, etc. in legacy stacks — confounds attribution. [community]

DSIP / sleep agents: Sometimes discussed when anxiety and sleep interact; separate goals. [community]

Source context — Selank/Semax IN experiences: Mixed compounds and variants; paired report cannot establish Selank-only cognitive benefit. Replies recommend regimens and include preparation material, which are not adopted. Route superiority and analog potency claims are opinions.

A calming reputation does not prevent activation or low mood. The 250 mcg account described depression-like episodes, rumination, chest tightness and vivid dreams. The recent 100 mcg/spray account described racing thoughts, faster heart rate and poor sleep on later nights. A reply's accumulation explanation is speculation, not a diagnosis. Negative experience on Selank: any alternatives? (Community discussion · Accessed 2026-09-30) · My recent experience with Selank (Community discussion · Accessed 2026-09-30)

Irritation, headache and unwanted flatness also appear. Preserved reports include burning or drip after nasal use, head pressure, fatigue, reduced motivation, dullness and injection-site irritation. Their frequency is not established. Early discomfort being called adaptation does not show it was harmless. Day 10 of 14 day Selank cycle: 750 mcg intranasal (Community discussion · Accessed 2026-09-30)

Product quality and interaction uncertainty matter. FDA flags possible immune reactions from aggregation or peptide impurities and missing human safety information for compounded Selank acetate. Favorable accounts involving SSRIs, stimulants or other peptides do not verify combinations. Preserved harm-reduction discussion cautions against casually adding alcohol or benzodiazepines. FDA: bulk substances that may present significant safety risks (Official context · Accessed 2026-09-30) · Day 10 of 14 day Selank cycle: 750 mcg intranasal (Community discussion · Accessed 2026-09-30)

Source context — Negative experience on Selank: any alternatives?: Route unstated; daily opening clarified as five days/week. Other stack use not fully described. No causal diagnosis, verified severity or clinical follow-up. Deleted replies are not reconstructed.

Source context — My recent experience with Selank: Nasal spray content unverified; timing and heart rate self-reported. Other historical medication responses do not establish current co-use. The few-hours half-life and accumulation explanation have no supporting measurement. No prevalence inference.

Source context — Day 10 of 14 day Selank cycle: 750 mcg intranasal: Anonymous uncontrolled accounts; no product assay. Nasal post covers day ten of planned 14 days, not a completed trial. Same-author later persistence is unverified. Separate injected account lacks frequency and includes sertraline. Claims about adaptation, route superiority and hundreds of users are not accepted.

Source context — FDA: bulk substances that may present significant safety risks: Compounding risk assessment, not quantified incidence or a diagnosis for an individual reporter. Does not validate a community product or settle every jurisdiction's rules.